U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 3

1.
Figure 1)

Figure 1). From: Montelukast as add-on therapy with inhaled corticosteroids or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial).

A statistically and clinically significant decrease from baseline to eight weeks in the mean (± 95%CI) Asthma Control Questionnaire (ACQ) score (P<0.00)

Paul K Keith, et al. Can Respir J. 2009 May-Jun;16(Suppl A):17A-24A.
2.
Figure 2)

Figure 2). From: Montelukast as add-on therapy with inhaled corticosteroids or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial).

A statistically and clinically significant decrease from baseline to eight weeks in the mean (± 95%CI) Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) scores (P<0.001)

Paul K Keith, et al. Can Respir J. 2009 May-Jun;16(Suppl A):17A-24A.
3.
Figure 3)

Figure 3). From: Montelukast as add-on therapy with inhaled corticosteroids or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial).

A statistically significant change from baseline to eight weeks in the mean (± 95%CI) global satisfaction score for patients and physicians (P<0.001)

Paul K Keith, et al. Can Respir J. 2009 May-Jun;16(Suppl A):17A-24A.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center